International Journal of Clinical Practice / 2022 / Article / Tab 1 / Review Article
Efficacy of ω -3 Polyunsaturated Fatty Acids in Patients with Lung Cancer Undergoing Radiotherapy and Chemotherapy: A Meta-Analysis Table 1 Characteristics of the included studies.
Author Year Country Area Diagnosis Basic treatment Intervention Intervention duration Dose Control Intervention sample Control sample Outcomes Sánchez-Lara et al. [12 ] 2014 Mexico North America NSCLC Chemotherapy EPA 6 weeks EPA 2.2 g/d Standard recipe 46 46 abcdef Finocchiaro et al. [13 ] 2012 Italy Europe NSCLC Chemotherapy EPA + DHA 66 days EPA 510 mg + DHA 340 mg/d Olive oil 13 14 acdef Van der Meij et al. [14 ] 2010 Netherlands Europe NSCLC Chemotherapy + radiotherapy EPA + DHA 5 weeks EPA 2.02 g + DHA 0.92 g/d Isocaloric supplements 20 20 acd Lu et al. [15 ] 2018 China Asia NSCLC Chemotherapy + radiotherapy EPA + DHA 6 weeks EPA 510 mg + DHA 200 mg/d Common diets 77 60 aef Murphy et al. [16 ] 2011 Canada Europe NSCLC Chemotherapy EPA 6 weeks EPA 2.2 g/d Common diets 16 24 a Cheng et al. [17 ] 2021 China Asia NSCLC + SCLC Chemotherapy EPA + DHA 12 weeks EPA 1.6 g + DHA 0.8 g/d Sunflower seed oil 29 29 abcef Pastore et al. [18 ] 2014 Brazil South America NSCLC + SCLC Chemotherapy EPA 4 weeks EPA2.2 g/d Isocaloric supplements 8 8 e
Note: NSCLC: non-small-cell lung cancer; SCLC: small cell lung cancer; a: weight change; b: albumin change; c: energy intake at the end of the intervention; d: protein intake at the end of the intervention; e: CRP change; f: TNF-α change.
